Last reviewed · How we verify

NCT04971993: SWAN

Step and Walking Pattern From Cardiac Monitor Study

Terminated Last updated 13 December 2023
What this trial tests

trial testing Wearable Cardiac Monitor in Heart Failure NYHA Class II in 40 participants. Terminated before completion.

Timeline
5 January 2022
Primary endpoint
11 October 2023
11 October 2023

Quick facts

Lead sponsorBoston Scientific Corporation
StatusTerminated
Study typeOBSERVATIONAL
Enrollment40
Start date5 January 2022
Primary completion11 October 2023
Estimated completion11 October 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Boston Scientific Corporation — full company profile →

Who can join

18 and older, any sex, with Heart Failure NYHA Class II or Heart Failure NYHA Class III. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To understand the feasibility of characterizing walking patterns in heart failure subjects and subjects at risk for arrhythmias using an investigational wearable monitor called the SWAN study system.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Heart Failure NYHA Class II

Currently open trials in the same condition.

Other Boston Scientific Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04971993.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing